<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Volatility on FinanClub</title>
    <link>https://finan.club/tags/volatility/</link>
    <description>Recent content in Volatility on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 19 Feb 2024 09:04:51 +0000</lastBuildDate><atom:link href="https://finan.club/tags/volatility/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>SWN</title>
      <link>https://finan.club/us/swn/</link>
      <pubDate>Mon, 19 Feb 2024 09:04:51 +0000</pubDate>
      
      <guid>https://finan.club/us/swn/</guid>
      <description>score:29
Chances: Southwestern Energy (SWN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.</description>
    </item>
    
    <item>
      <title>OWL</title>
      <link>https://finan.club/us/owl/</link>
      <pubDate>Thu, 18 Jan 2024 09:06:03 +0000</pubDate>
      
      <guid>https://finan.club/us/owl/</guid>
      <description>score:46
Chances: Blue Owl Capital Inc. and Blue Owl Capital Corporation are both scheduled to release their financial results for the fourth quarter, providing potential opportunities for investors to assess the performance of these companies. Risks: The volatility of the stock market and potential fluctuations in the financial performance of Blue Owl Capital Inc.</description>
    </item>
    
    <item>
      <title>MRNA</title>
      <link>https://finan.club/us/mrna/</link>
      <pubDate>Wed, 17 Jan 2024 09:04:41 +0000</pubDate>
      
      <guid>https://finan.club/us/mrna/</guid>
      <description>score:-55
Chances: Moderna&amp;rsquo;s product pipeline includes a wide range of modalities, such as prophylactic vaccines, cancer vaccines, and localized regenerative therapeutics, providing opportunities for significant future growth. The company&amp;rsquo;s focus on intratumoral immuno-oncology and systemic intracellular therapeutics reflects a strong commitment to addressing complex medical challenges with innovative solutions.</description>
    </item>
    
  </channel>
</rss>
